Published in Semin Oncol on August 01, 2001
Impact of Radiation Therapy on Breast Conservation in DCIS | NCT02248662
Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst (2010) 4.57
Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol (2009) 3.70
Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst (2011) 3.54
Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol (2010) 3.27
A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst (2013) 2.56
Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. J Clin Oncol (2012) 2.40
Network meta-analysis of margin threshold for women with ductal carcinoma in situ. J Natl Cancer Inst (2012) 1.87
What is the malignant nature of human ductal carcinoma in situ? Nat Rev Cancer (2010) 1.86
Comparative effectiveness of ductal carcinoma in situ management and the roles of margins and surgeons. J Natl Cancer Inst (2011) 1.69
Patterns and correlates of local therapy for women with ductal carcinoma-in-situ. J Clin Oncol (2005) 1.53
Modeling the effectiveness of initial management strategies for ductal carcinoma in situ. J Natl Cancer Inst (2013) 1.45
Downregulation of miR-140 promotes cancer stem cell formation in basal-like early stage breast cancer. Oncogene (2013) 1.41
Use of tamoxifen before and during pregnancy. Oncologist (2011) 1.16
Interdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer: Short version - AWMF Registry No.: 032-045OL AWMF-Register-Nummer: 032-045OL - Kurzversion 3.0, Juli 2012. Geburtshilfe Frauenheilkd (2013) 1.14
A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone. Breast Cancer Res Treat (2015) 1.12
Local outcomes in ductal carcinoma in situ based on patient and tumor characteristics. J Natl Cancer Inst Monogr (2010) 1.06
Characterization of a stem-like subpopulation in basal-like ductal carcinoma in situ (DCIS) lesions. J Biol Chem (2013) 1.02
[Prognostic factors in ductal carcinoma in situ]. Pathologe (2006) 1.00
Breast-conserving surgery with or without radiotherapy in women with ductal carcinoma in situ: a meta-analysis of randomized trials. Radiat Oncol (2007) 0.99
The impact of adding radiation treatment after breast conservation surgery for ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr (2010) 0.99
The impact of surgery, radiation, and systemic treatment on outcomes in patients with ductal carcinoma in situ. J Natl Cancer Inst Monogr (2010) 0.99
Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting. Breast Cancer Res (2009) 0.97
NSABP breast cancer clinical trials: recent results and future directions. Clin Med Res (2003) 0.94
Breast-conserving surgery with or without radiotherapy vs mastectomy for ductal carcinoma in situ: French Survey experience. Br J Cancer (2009) 0.93
Association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma in situ. J Natl Cancer Inst Monogr (2010) 0.93
Significance of immunohistochemistry in breast cancer. World J Clin Oncol (2014) 0.92
The diagnosis and management of pre-invasive breast disease: problems associated with management of pre-invasive lesions. Breast Cancer Res (2003) 0.92
PI-3 kinase activity is necessary for ERK1/2-induced disruption of mammary epithelial architecture. Breast Cancer Res (2009) 0.90
The Association of Surgical Margins and Local Recurrence in Women with Ductal Carcinoma In Situ Treated with Breast-Conserving Therapy: A Meta-Analysis. Ann Surg Oncol (2016) 0.90
Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ. Breast Cancer Res Treat (2013) 0.90
Perioperative breast MRI is not associated with lower locoregional recurrence rates in DCIS patients treated with or without radiation. Ann Surg Oncol (2014) 0.90
Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study. J Clin Oncol (2015) 0.90
The significance of the Van Nuys prognostic index in the management of ductal carcinoma in situ. World J Surg Oncol (2008) 0.89
Treatment patterns for ductal carcinoma in situ from 2000-2010 across six integrated health plans. Springerplus (2015) 0.89
Disease-free survival by treatment after a DCIS diagnosis in a population-based cohort study. Breast Cancer Res Treat (2013) 0.88
Ductal carcinoma in situ: what the pathologist needs to know and why. Int J Breast Cancer (2013) 0.86
Long-term results of forward intensity-modulated radiation therapy for patients with early-stage breast cancer. Radiat Oncol J (2013) 0.86
Radiation therapy for ductal carcinoma in situ: a decision analysis. Cancer (2011) 0.85
Pathologic characteristics of second breast cancers after breast conservation for ductal carcinoma in situ. Cancer (2012) 0.85
Ductal carcinoma in situ: recent advances and future prospects. Int J Surg Oncol (2012) 0.84
Local and systemic outcomes in DCIS based on tumor and patient characteristics: the radiation oncologist's perspective. J Natl Cancer Inst Monogr (2010) 0.84
Chromosomal copy number alterations for associations of ductal carcinoma in situ with invasive breast cancer. Breast Cancer Res (2015) 0.84
Radiotherapy after conservative surgery in ductal carcinoma in situ of the breast: a review. Int J Surg Oncol (2012) 0.84
A Comparison of Tumor Biology in Primary Ductal Carcinoma In Situ Recurring as Invasive Carcinoma versus a New In Situ. Int J Breast Cancer (2013) 0.84
Modeling of the growth kinetics of occult breast tumors: role in interpretation of studies of prevention and menopausal hormone therapy. Cancer Epidemiol Biomarkers Prev (2012) 0.83
Breast cancer therapy-associated cardiovascular disease. Nat Rev Clin Oncol (2015) 0.83
The impact of systemic therapy following ductal carcinoma in situ. J Natl Cancer Inst Monogr (2010) 0.83
Relationship between clinical and pathologic features of ductal carcinoma in situ and patient age: an analysis of 657 patients. Am J Surg Pathol (2009) 0.82
Communication between patients and providers and informed decision making. J Natl Cancer Inst Monogr (2010) 0.82
Ductal carcinoma in situ of the breast. Int J Surg Oncol (2012) 0.82
Long-term outcomes of ductal carcinoma in situ of the breast: a systematic review, meta-analysis and meta-regression analysis. BMC Cancer (2015) 0.81
Regression of ductal carcinoma in situ after treatment with acupuncture. J Altern Complement Med (2013) 0.81
Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotype. Br J Cancer (2013) 0.79
Predictors for local invasive recurrence of ductal carcinoma in situ of the breast: a meta-analysis. Eur J Cancer Prev (2016) 0.79
A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ. J Natl Cancer Inst (2013) 0.78
Conservative treatment of breast ductal carcinoma in situ: results of an Italian multi-institutional retrospective study. Radiat Oncol (2012) 0.78
Characterization and treatment of local recurrence following breast conservation for ductal carcinoma in situ. Ann Surg Oncol (2014) 0.78
Lapatinib inhibits stem/progenitor proliferation in preclinical in vitro models of ductal carcinoma in situ (DCIS). Cell Cycle (2013) 0.78
The importance of systemic therapy in minimizing local recurrence after breast-conserving surgery: the NSABP experience. J Surg Oncol (2014) 0.78
Memorial sloan-kettering cancer center: two decades of experience with ductal carcinoma in situ of the breast. Int J Surg Oncol (2012) 0.77
Study of Estrogen Receptor and Progesterone Receptor Expression in Breast Ductal Carcinoma In Situ by Immunohistochemical Staining in ER/PgR-Negative Invasive Breast Cancer. ISRN Oncol (2011) 0.77
Vav2 protein overexpression marks and may predict the aggressive subtype of ductal carcinoma in situ. Biomark Res (2014) 0.77
Investigational Paradigms in Downscoring and Upscoring DCIS: Surgical Management Review. Int J Surg Oncol (2012) 0.77
Intraductal therapy of ductal carcinoma in situ: a presurgery study. Clin Breast Cancer (2013) 0.77
Characteristics of second breast events among women treated with breast-conserving surgery for DCIS in the community. Breast Cancer Res Treat (2016) 0.76
Breast conservation therapy for ductal carcinoma in situ (DCIS): does presentation of disease affect long-term outcomes? Int J Clin Oncol (2013) 0.76
Effect of radiotherapy on survival of women with locally excised ductal carcinoma in situ of the breast: a Surveillance, Epidemiology, and End Results population-based analysis. Onco Targets Ther (2015) 0.75
Clinical experience of patients with ductal carcinoma in situ of the breast treated with breast-conserving surgery plus radiotherapy: a preliminary report. Cancer Res Treat (2005) 0.75
Clinical outcomes of ductal carcinoma in situ of the breast treated with partial mastectomy without adjuvant radiotherapy. Yonsei Med J (2012) 0.75
The role of preoperative bilateral breast magnetic resonance imaging in patient selection for partial breast irradiation in ductal carcinoma in situ. Int J Surg Oncol (2012) 0.75
Breast Ductal Carcinoma In Situ: A Literature Review of Adjuvant Hormonal Therapy. Oncol Rev (2016) 0.75
Structural estimates of treatment effects on outcomes using retrospective data: an application to ductal carcinoma in situ. Med Care Res Rev (2011) 0.75
Ductal carcinoma in situ: what can we learn from clinical trials? Int J Surg Oncol (2012) 0.75
The half century of clinical trials of the National Surgical Adjuvant Breast And Bowel Project. Semin Oncol (2008) 0.75
Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast. Breast Cancer Res Treat (2016) 0.75
Role of the radiotherapy boost on local control in ductal carcinoma in situ. Int J Surg Oncol (2012) 0.75
Clinical Utility of the 12-Gene DCIS Score Assay: Impact on Radiotherapy Recommendations for Patients with Ductal Carcinoma In Situ. Ann Surg Oncol (2016) 0.75
Final results from a multicenter prospective study ( JROSG 05-5) on postoperative radiotherapy for patients with ductal carcinoma in situ with an involved surgical margin or close margin widths of 1 mm or less. J Radiat Res (2015) 0.75
Ductal Carcinoma In Situ of the Breast: Evaluating the Role of Radiation Therapy in the Management and Attempts to Identify Low-risk Patients. Am J Clin Oncol (2015) 0.75
The landmark surgical trials of the National Surgical Adjuvant Breast and Bowel Project. World J Surg (2006) 0.75
TRANSFAC: transcriptional regulation, from patterns to profiles. Nucleic Acids Res (2003) 29.26
TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes. Nucleic Acids Res (2006) 22.20
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst (1998) 22.10
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol (1998) 9.32
Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med (1985) 8.45
Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet (1999) 7.72
Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst (1994) 6.37
Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med (1989) 6.37
Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol (1997) 6.35
A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med (1989) 6.24
Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr (2001) 5.74
1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. N Engl J Med (1975) 5.48
Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med (1993) 5.39
Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst (1996) 5.28
Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med (1995) 5.27
Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst (2001) 4.84
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04) J Clin Oncol (1999) 4.79
Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer (1999) 4.70
Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst (1997) 4.32
The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4). Cancer (1975) 4.12
The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol (1993) 4.09
Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol (1998) 3.94
Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer (1983) 3.94
Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med (1985) 3.41
Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst (2000) 3.27
The effects of age and gender on sleep EEG power spectral density in the middle years of life (ages 20-60 years old). Psychophysiology (2001) 3.15
Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol (1990) 3.12
The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast. Surg Gynecol Obstet (1981) 3.11
Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst (1988) 3.09
Outcomes among African-Americans and Caucasians in colon cancer adjuvant therapy trials: findings from the National Surgical Adjuvant Breast and Bowel Project. J Natl Cancer Inst (1999) 3.07
Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02. J Clin Oncol (1990) 2.89
erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst (1998) 2.85
Significance of ipsilateral breast tumour recurrence after lumpectomy. Lancet (1991) 2.70
Comparison of radical mastectomy with alternative treatments for primary breast cancer. A first report of results from a prospective randomized clinical trial. Cancer (1977) 2.16
Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst (2001) 2.12
Detection and significance of occult axillary node metastases in patients with invasive breast cancer. Cancer (1978) 2.10
Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol No. 4). V. Significance of axillary nodal micro- and macrometastases. Cancer (1978) 2.08
Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol (1989) 2.03
A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med (1989) 1.99
Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol (1983) 1.94
The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol (1994) 1.94
Ten year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet (1975) 1.91
Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol (2001) 1.87
HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst (2000) 1.85
Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst (1988) 1.72
Trauma and the localization of tumor cells. Cancer (1967) 1.71
Pathologic findings from the National Surgical Adjuvant Breast Project (protocol 6). II. Relation of local breast recurrence to multicentricity. Cancer (1986) 1.70
Interstitial hypertension in human breast and colorectal tumors. Cancer Res (1992) 1.67
Pathologic findings from the National Surgical Adjuvant Project for Breast Cancers (protocol no. 4). X. Discriminants for tenth year treatment failure. Cancer (1984) 1.65
A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum: a progress report of National Surgical Breast and Bowel Project Protocol R-03. Dis Colon Rectum (1997) 1.58
Thermal expansion measurements of frozen biological tissues at cryogenic temperatures. J Biomech Eng (1998) 1.56
Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol (1997) 1.56
Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst (1997) 1.55
Estimation of mucosal mucin as an aid in the differentiation of Crohn's disease of the colon and chronic ulcerative colitis. Am J Clin Pathol (1967) 1.54
Tumor size and regional lymph node metastasis in colorectal cancer. A preliminary analysis from the NSABP clinical trials. Cancer (1983) 1.51
Experimental renal vein constriction. Its relation to renal lesions observed in human renal vein thrombosis and the nephrotic syndrome. Lab Invest (1968) 1.49
The contribution of recent NSABP clinical trials of primary breast cancer therapy to an understanding of tumor biology--an overview of findings. Cancer (1980) 1.48